Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;12(5):783-93; discussion 793-4.
doi: 10.1007/s11605-007-0391-9. Epub 2008 Mar 4.

Quality of life in pancreatic cancer: analysis by stage and treatment

Stefano Crippa  1 , Ismael Domínguez, J Ruben Rodríguez, Oswaldo Razo, Sarah P Thayer, David P Ryan, Andrew L Warshaw, Carlos Fernández-del Castillo
Affiliations

Quality of life in pancreatic cancer: analysis by stage and treatment

Stefano Crippa et al. J Gastrointest Surg. 2008 May.

Abstract

In pancreatic cancer patients, survival and palliation of symptoms should be balanced with social and functional impairment, and for this reason, health-related quality of life measurements could play an important role in the decision-making process. The aim of this work was to evaluate the quality of life and survival in 92 patients with different stages of pancreatic adenocarcinoma who underwent surgical and/or medical interventions. Patients were evaluated with the Functional Assessment of Cancer Therapy questionnaires at diagnosis and follow-up (3 and 6 months). At diagnosis, 28 patients (30.5%) had localized disease (group 1) and underwent surgical resection, 34 (37%) had locally advanced (group 2), and 30 (32.5%) metastatic disease (Group 3). Improvement in quality of life was found in group 1, while in group 3, it decreased at follow-up (p=0.03). No changes in quality of life in group 2 were found. Chemotherapy/chemoradiation seems not to significantly modify quality of life in groups 2 and 3. Median survival time for the entire cohort was 9.8 months (range, 1-24). One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p=0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life.

PubMed Disclaimer

Figures

Figure 1
Figure 1
a Kaplan–Meier overall survival curve in 92 patients with pancreatic cancer. One- and 2-year survival was 39 and 23 months. b Kaplan–Meier survival curves in patients with localized (group 1, n = 28), locally advanced (group 2, n = 34), and metastatic pancreatic cancer (group 3, n = 30) at initial presentation. One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3, respectively (P = 0.001).
Figure 2
Figure 2
Clinical changes in health-related quality of life (HQOL) of patients with local (group 1), locally advanced (group 2), and metastatic (group 3) pancreatic cancer. Square and triangle Meaningful important differences (MID).
Figure 3
Figure 3
Clinical changes in HQOL in patients affected by locally advanced and metastatic pancreatic cancer with or without biliary/enteral stents. Square and triangle Meaningful important differences (MID).
Figure 4
Figure 4
Clinical changes in HQOL of patients with locally advanced and metastatic pancreatic cancer who underwent chemotherapy or chemoradiation. Square Meaningful important differences (MID).
Figure 5
Figure 5
Clinical changes in HQOL of patients with locally advanced and metastatic pancreatic cancer who underwent celiac block or did not. Square, triangle; and circle Meaningful Important Differences (MID).
See this image and copyright information in PMC

References

    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer Statistics, 2005 CA. Cancer J Clin. 2005;55:10–30. - PubMed
    1. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH. Pancreaticoduo-denectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg. 2002;236:355–366. - PMC - PubMed
    1. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–2902. - PMC - PubMed
    1. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic caner: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the national cancer database. J Am Coll Surg. 1999;189:1–7. - PubMed
    1. Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Coletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGrinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150–158. - PubMed

Publication types